GlassScriptPhysician profile
Cody Mitchell Phillips
NPI 1669944971
$3,278.07
in general payments reported to CMS, 2019-2025
13 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $919 · 2024: $1,150 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,092.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.13 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $622.38 | 2023-2025 | |
| Lilly USA, LLC | $463.32 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $401.55 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $307.81 | 2023-2025 | |
| Amgen INC. | $236.10 | 2022-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $118.27 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.89 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.00 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $82.29 | 2022-2025 | |
| Glaxosmithkline, LLC. | $71.57 | 2023-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $64.32 | 2022-2023 | Spravato |
| Dexcom, INC. | $62.44 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.